Search results for "LBAS"

showing 8 items of 18 documents

Premières données sur les vestiges funéraires de l’âge du Bronze à Saint-Vulbas (Ain)

2018

National audience

archéologie funéraire[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and PrehistorySaint-Vulbasâge du Bronze[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistoryAinComputingMilieux_MISCELLANEOUS
researchProduct

L’alba in forma di romanza: sul tipo strofico e musicale di 'Reis glorios' (BdT 242,64)

2018

La famosa alba attribuita da alcuni canzonieri a Giraut de Borneil è stata ultimamente al centro di una serie di autorevoli contributi, concomitanti alla scoperta di un’antica traduzione italiana del testo provenzale, che hanno cercato di definirne meglio lo stemma, il testo critico e l’interpretazione. In questo contributo si discutono gli aspetti formali di Reis glorios con riguardo a tutta la tradizione (anche indiretta) e si propone d’individuare nel suo tipo metrico e musicale la cosiddetta ‘strofa di romanza’: essa caratterizza in particolare il corpus di canzoni di tela antico-francesi col quale l’alba provenzale mostra di condividere anche elementi stilistici e retorici. Questa agni…

filologia provenzalemetrica e musicaLinguistics and LanguageLiterature and Literary TheoryGiraut de BorneilLanguage and Linguisticschansons de toilealbas provenzali
researchProduct

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.

2020

Abstract Background In Europe, increases in HCV infection have been observed over the last two decades in MSM, making them a key population for recently acquired HCV. Alternative combinations of direct-acting antiviral agents against early HCV infection need to be assessed. Patients and methods In this pilot trial, MSM with recently acquired genotype 1 or 4 HCV infection were prospectively included and received 8 weeks of oral grazoprevir 100 mg and elbasvir 50 mg in a fixed-dose combination administered once daily. The primary endpoint was sustained virological response evaluated 12 weeks after the end of treatment (EOT) (SVR12). Secondary endpoints were the virological characterization of…

hepatitis C virusCyclopropanesMaleadverse eventmen who have sex with menHepacivirusmedicine.disease_causeSexual and Gender Minoritiesblood HIV RNA0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesfollow-upClinical endpointMedicinePharmacology (medical)infections030212 general & internal medicinehepatitis ceducation.field_of_studySulfonamideshepatitis c rnaImidazolesvirus diseasesHepatitis Cvirologyhepatitis C virus genotype 13. Good healthEuropeInfectious DiseasesGrazoprevirRNA Viral030211 gastroenterology & hepatologyDrug Therapy CombinationMicrobiology (medical)medicine.medical_specialtyElbasvirGenotypeHepatitis C virusPopulationelbasvirAntiviral Agentsreinfection03 medical and health sciencesInternal medicineQuinoxalinesHumansHomosexuality MaleAdverse effecteducationplasmasuicideBenzofuransPharmacologybusiness.industrySurrogate endpointHIVgrazoprevirHepatitis C Chronicmedicine.diseaseAmidessurrogate endpoints[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyQuality of LifeCarbamatesbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

2020

Background&aims The presence of baseline resistance-associated substitutions (RASs) reduced sustained virologic response (SVR) rates in chronic hepatitis C virus (HCV) genotype 1a infected patients treated with Elbasvir/Grazoprevir (EBR/GZR). This study aimed to evaluate the frequency of NS5A RASs and treatment outcomes in patients for whom EBR/GZR was intended. Methods We sequenced NS5A in 832 samples from German genotype1a-infected DAA-naive patients population-based, which were collected in the European Resistance Database. Treatment outcomes and clinical parameters were evaluated in 519 of these patients retrospectively. Results Overall, 6.5% of patients harbored EBR-specific NS5A RASs …

medicine.medical_specialtyElbasvirHepatologybusiness.industryHepatitis C virusTreatment outcomemedicine.disease_causeGastroenterology03 medical and health sciences0302 clinical medicineGenotype 1bGrazoprevir030220 oncology & carcinogenesisInternal medicineHepatitis C virus genotypeMedicine030211 gastroenterology & hepatologyIn patientbusinessNS5ALiver International
researchProduct

Phase III, Multicenter Open-Label Study to Investigate the Efficacy of Elbasvir and Grazoprevir Fixed-Dose Combination for Eight Weeks in Treatment-N…

2020

Background: Genotype 1b is the most common HCV genotype worldwide, accounting for the largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing treatment duration can improve adherence, reduce drug exposure and cost. Accordingly, we evaluated the efficacy of eight weeks fixed dose combination of grazoprevir-elbasvir in treatment-naive patients, with non-severe fibrosis. Methods: HCV mono-infected and treatment naive patients with non-severe fibrosis (Fibroscan®<9·5kPa and Fibrotest®<0·59) were enrolled in a study which included 117 patients. Genotyping by sequencing identified five patients with non-1b genotype (two GT1a, one GT1h, one GT1e and one GT1l). Thus, we…

medicine.medical_specialtyElbasvirbusiness.industryFixed-dose combinationHepatitis Cmedicine.diseaseClinical investigatorGrazoprevirInformed consentInternal medicineGood clinical practicemedicinebusinessViral loadSSRN Electronic Journal
researchProduct

Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: a pro…

2019

Introduction: In a previous study, based on PITER cohort data, it was reported that of patients, undergoing direct acting antiviral (DAA) therapy, 30%-44%, are at risk of potential drug-drug interactions (DDI). Aim: We aimed to evaluate the prospective profile of elbasvir/grazoprevir (EBR/GZR) efficacy and safety combined with real life comedication profile. Method: Data from 312 patients (mean age 63 ± 10 years; 44% male, 90% of genotype 1.85% fibrosis stage ≤ F3, 15% with child A cirrhosis), enrolled in PITER by 15 clinical centers and treated with EBR/GZR, with at least three months of follow up after the end of treatment, were evaluated. Comedication profiles (no changes, drugs interrup…

medicine.medical_specialtyHepatologybusiness.industryDrug-drug interactionGastroenterologyelbasvir grazoprevir efficacy drug-drug interaction Hepatitic HCV Piter cohortReal life dataViral infectionProspective analysisChronic hepatitisInternal medicineCohortmedicineElbasvir GrazoprevirIn patientbusinessDigestive and Liver Disease
researchProduct

Latvijas Brīvo arodbiedrību savienības iesaiste darba attiecību regulēšanā

2016

Maģistra darbā autore ir veikusi LBAS gadījuma izpēti. Darba mērķis ir noskaidrot LBAS iesaisti darba tiesisko attiecību regulēšanā. Pētījumā izmantotas sociālo tīklu un konfliktu teorijas, apskatīts deregulācijas procesu skaidrojums dažādu autoru darbos. Maģistra darbā analizētas 9 daļēji strukturētas intervijas ar LBAS pārstāvjiem un sociālajiem partneriem. Autore secina, ka sociālo tīklu struktūrai ir būtiska nozīme lēmumu pieņemšanas procesos. Respondenti pozitīvi ir novērtējuši mediācijas procesa nepieciešamību konfliktu novēršanai. LBAS būtu jāpārskata savu pieeju darba tirgus segmentācijas procesiem, kas līdz šim ir tikuši nepietiekami novērtēti, veicinot diskriminācijas veidošanos d…

segmentācijaSocioloģijaLBASmediācijaarodbiedrību konfederācijadarba attiecības
researchProduct

Enclos fossoyés et sépultures de l'âge du Bronze à Saint-Vulbas : la fouille du PIPA, lot 7, secteur 4000 (Ain, Auvergne-Rhône-Alpes)

2017

sépulture[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and PrehistorySaint-Vulbasâge du Bronze[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and PrehistoryAuvergne-Rhône-AlpesfouilleAinEnclos fossoyés
researchProduct